About: fang

Key Highlights:Hiring activity in Singapore saw recovery with a 3% month-on-month growth while witnessing an annual dip of 5% in February’25Advertising, Public Relations & Media sector and the Education sector lead with 7% month-on-month growth in February '25Hiring for Software, Hardware, and Telecom roles record the highest growth at 2% month-on-month Legal sector saw the strongest annual growth at 19% year-on-yearSINGAPORE, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - foundit (formerly Monster APAC & ME), one of the leading jobs and talent platform, today published the foundit Insights Tracker (fit) Singapore for February 2025. The Singapore fit report highlights growth in the Advertising and Education sectors alongside rising demand for technology professionals.The tracker reveals an overall year-on-year (YoY) decline of 5% in hiring activity across sectors, as the index dropped from 108 in February 2024 to 103 in February 2025. However, a month-on-month (MoM) analysis indicates a 3% uptick,Commenting on Singapore's job trends for February 2025, V Suresh, CEO, foundit, said,“The February 2025 foundit Insights Tracker signals a promising recovery in Singapore’s job market. While year-on-year figures reflect ongoing economic recalibration, the month-on-month growth indicates a resurgence in hiring activity. The robust expansion of sectors such as Advertising, Media, and Education, coupled with the growing demand for technology professionals, underscores shifting industry priorities and workforce evolution. As digital transformation accelerates, Singapore’s job landscape is stabilizing, with a strong emphasis on upskilling, adaptability, and future-ready talent."Advertising, and Education sectors lead industry growth, while Engineering and Retail sectors show strong improvementsThe Advertising, Market Research, Public Relations, Media, and Entertainment sector has emerged as a frontrunner in e-recruitment activity among all monitored industries, showing a 7% MoM growth in February 2025. This growth is driven by increased digital marketing efforts and brand-building strategies.Equally impressive, the Education sector also recorded 7% MoM growth in February 2025, reflecting a continued emphasis on workforce upskilling and professional development.Following these leaders, the Engineering, Construction, and Real Estate sector showed positive trends with 6% MoM growth, while the Retail, Trade, and Logistics sector experienced 5% MoM growth, both driven by sustainability initiatives and evolving business needs.Several sectors show modest growth while others remain stableThe Production/Manufacturing, Automotive, and Ancillary sector demonstrated positive hiring momentum with 5% MoM growth in February 2025.Several sectors showed more modest growth, with Hospitality & Travel, IT, Telecom/ISP, and BPO/ITES, BFSI, and Healthcare all registering 2% MoM increases, signalling steady job creation across these industries.Conversely, multiple sectors including Oil and Gas, Import/Export, Shipping/Marine, Government/PSU/Defence, and Consumer Goods/FMCG exhibited stagnant hiring activity with 0% MoM change.Technology roles lead demand among functionsIn terms of functions, Software, Hardware, and Telecom witnessed the highest demand in February 2025, with a 2% MoM increase. This trend underscores the growing need for tech talent amid ongoing digital transformation initiatives.Marketing & Communications, HR & Admin, Engineering/Production, Sales & Business Development, Medical Roles, and Legal roles all showed modest but positive growth at 1% MoM, indicating broad but measured hiring activity across professional functions.The roles in Legal experienced a robust   19% YoY increase in hiring activity, highlighting the rising need for legal professionals amid evolving regulatory landscapes, corporate expansions, and compliance requirements.However, Hospitality Roles, Customer Service, Finance & Accounts, and Purchase/Logistics/Supply Chain roles saw no changes (0% MoM), reflecting a period of stability in workforce demand across these functions.The foundit Insights Tracker is a comprehensive monthly analysis of online job posting activity conducted by foundit. Based on a real-time review of millions of employer job opportunities culled from a large, representative selection of online career outlets, the foundit Insights Tracker (FIT) presents a snapshot of employer online recruitment activity nationwide.About foundit - APAC & Middle Eastfoundit, formerly Monster (APAC & ME), is Asia’s leading jobs and talent platform offering comprehensive employment solutions to recruiters and job seekers across APAC & ME. In addition to its innovative AI-powered job search, foundit offers e-learning, assessments, and services related to resume creation and interview preparation. foundit has connected over 120 million job seekers across 18 countries with the right job roles and upskilling opportunities. Over the last two decades, the company has been a leader in the world of recruitment solutions and has launched cutting-edge tools to give recruiters access to passive candidates in addition to active ones. With its advanced technology, foundit is efficiently bridging the talent gap across industry verticals, experience levels, and geographies.Today, foundit is committed to enabling and connecting the right talent with the right opportunities by harnessing the power of deep tech to sharpen hyper-personalised job searches and offer precision hiring. Additionally, foundit has been recognised as a Great Place to Work, reflecting its dedication to fostering a supportive and dynamic work culture.To learn more about, foundit in APAC & Gulf, visit: www.foundit.sg |www.foundit.com.ph | www.foundit.my | www.foundit.in | www.founditgulf.com | http://www.foundit.hk | www.foundit.id For media inquiries or further information, please contactNamrata Sharma – Namrata.sharma@adfactorspr.comContact number - +65 81383034 Copyright 2025 ACN Newswire via SeaPRwire.com.

- ComfortDelGro, a leading multi-modal mobility transport operator, introduces a new purpose statement to reflect its commitment to driving positive impact for a better future. - Refreshed logo and corporate identity underscores the company’s journey as a global, progressive, and collaborative mobility leader. SINGAPORE, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - ComfortDelGro Corporation Limited (SGX:C52) (“ComfortDelGro” or, “The Group”) today, unveiled its refreshed corporate brand, comprising a new purpose statement and modern visual identity that signifies a step forward in the company’s evolution into a global multi-modal transport leader. The Group has made significant strides in growing its international business, winning bus and rail tenders in Europe and Australia, as well as building leading positions for its point-to-point mobility businesses in key markets. With a presence in 13 countries, 24,500 employees, an operating fleet of over 54,000 vehicles and a rail network of 343 kilometres in operation and under mobilisation, ComfortDelGro is one of the largest land transport companies in the world. ComfortDelGro Managing Director/Group CEO Cheng Siak Kian said, “Our purpose statement – Mobility for a better future, drives us to reimagine mobility as a catalyst for positive impact as we accelerate our growth and navigate new horizons. It reflects our commitment to addressing the changing needs of our stakeholders as a global multi-modal transport leader. At the same time, it aligns the Group’s diverse operations and workforce under the common goal of building a purpose-driven and values-led organisation.” ComfortDelGro Chairman Mark Greaves added, “The transport landscape is evolving, and so is ComfortDelGro. We are committed to sustainable mobility, powered by innovation and driven by collaboration. This brand refresh underpins our journey forward as a global, progressive, and collaborative mobility company while building on the strong foundation of our businesses and our rich heritage. Our purpose ‘Mobility for a better future’ will guide us as we continue to create long-term value for our stakeholders, shape the future of transportation, and contribute to a more sustainable and connected world." Driven by our new purpose: Mobility for a better futureA modern identityComplementing our purpose statement is an updated ComfortDelGro logo that symbolises the company’s journey forward and its commitment to delivering innovative, world-class mobility solutions. Key elements include:A refined blue hue, representing reliability, trust, and customer confidence.A streamlined lowercase font, conveying approachability and collaboration.An enhanced arrow motif, reinforcing the company’s forward-thinking and dynamic approach.The updated brand and corporate identity will be gradually implemented in stages across the Group’s global operations.Media Assets:High-resolution images can be downloaded here: https://fromsmash.com/cdgbrandrefreshAbout ComfortDelGro CorporationComfortDelGro is a leading multi-modal transport operator offering a comprehensive suite of transportation solutions. Our extensive network spans public transport including buses and rail, point-to-point transport with taxis and private hire cars as well as business-to-business mobility solutions. Every day, millions rely on our services across 13 countries including; Singapore, Australia, the United Kingdom, New Zealand, China, Ireland, Sweden, France, Malaysia, Spain, Portugal, Greece, and the Netherlands. As a global operator, we play an important role in steering the transition towards a low-carbon economy. With about 60% of our owned fleet consisting of cleaner energy vehicles, we support governments and cities in enabling inclusive and sustainable transport systems. For our efforts, ComfortDelGro has been included in the Dow Jones Best-in-Class Indices since 2019, the only Singaporean transport company in the index. Media Contact Information:Group Corporate Communications  ComfortDelGro Corporation Limited groupcorpcomms@comfortdelgro.com  Copyright 2025 ACN Newswire via SeaPRwire.com.

Financial Highlights For the Year Ended 31 December RMB20242023Change RMB’BillionRMB’Billion(%)Revenue28.8726.20+10.2%Gross profit margin (%)81.5%81.0%+0.5pptSelling and administrative expenses to revenue ratio (%) *42.1%42.2%-0.1pptR&D expenses to revenue ratio (%)17.6%16.8%+0.8pptProfit for the year6.365.10+24.9%Profit attributable to owners of the parent **3.502.33+50.1%Adjusted non-HKFRS profit attributable tothe owners of the parent *** 3.46 2.59 +33.5%Basic earnings per share, based on adjusted non-HKFRS profit attributable to the owner of the parent (RMB cents) 18.90 13.97 +35.3%Sales of innovative products ****12.069.89+21.9%Share of revenue (%)41.8%37.8% Sales of new products*****10.098.05+25.4%Share of revenue (%)35.0%30.7% Dividend per share (HK cents)7.05.0+40.0%- Interim3.02.0+50.0%- Final4.03.0+33.3%*The total of selling and distribution costs and administrative expenses divided by revenue**The significant year-on-year increase in profit attributable to the owners of the parent was mainly driven by the notable growth in revenue and the gain on disposal of subsidiaries during the year***It refers to the basic earnings attributable to the owners of the parent after excluding impacts of discontinued operations, certain non-cash items and the share of profits and losses of associates and joint ventures.****Sales is the gross sales amount minus the sales discount. Innovative products include innovative drugs and biosimilars*****Products launched within five yearsDevelopment HighlightsOncology Innovative Drugs- Focus V (Anlotinib Hydrochloride Capsules) has been approved for seven indications. The marketing applications of three new indications have been submitted to the Center for Drug Evaluation of the China National Medical Products Administration (“CDE”), while another three pivotal clinical trials for new indications have shown positive results. The Group will submit new marketing applications to the CDE for these indications in the near future. In addition, anlotinib is in Phase III clinical studies for a number of new indications, including first-line non-squamous non-small cell lung cancer and first-line colorectal cancer. It is expected that marketing applications will be submitted gradually in the next few years.- Yilishu (Efbemalenograstim alfa Injection) has completed three global multi-center, randomized, and controlled pivotal Phase III clinical trials, and has been compared with the commonly used short-acting and long-acting G-CSF drugs in clinical practice, proving its efficacy and safety. In December 2023, Efbemalenograstim alfa was successfully included in the NRDL, and its sales volume accelerated in 2024, becoming an important contributor to the Group’s revenue growth.- Anfangning (Garsorasib Tablets) is a novel and highly effective KRAS G12C inhibitor that was approved for marketing by the NMPA in November 2024 for the treatment of advanced non-small cell lung cancer with KRAS G12C mutation that has received at least one systemic treatment. The Group will further explore the multi-indication potential of garsorasib, which is expected to become another blockbuster product in the oncology field.- Anbeisi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab for Injection), and Paletan (Pertuzumab Injection) were approved for marketing by the NMPA in February 2023, May 2023, July 2023, and December 2024, respectively. The rapid increase in the volume of these biosimilars in 2024 has accelerated the Group’s revenue growth.Liver Disease Innovative Drugs- Tianqing Ganmei (Magnesium Isoglycyrrhizinate Injection) is the fourth-generation of glycyrrhizic acid preparation that has been approved for three indications: chronic viral hepatitis, acute drug-induced liver injury, and improvement of liver dysfunction. Magnesium isoglycyrrhizinate is the world’s first 99.9% purified alpha-glycyrrhizic acid. It has the advantages of strong liver targeting, excellent anti-inflammatory effects, and good safety.- Lanifibranor (pan-PPAR agonist) is currently undergoing Phase III clinical trials worldwide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In July 2023, Lanifibranor was granted Breakthrough Therapy Designation by the CDE. Lanifibranor is China’s first MASH drug to enter Phase III clinical trials and is expected to fill the gap in China’s MASH market.Respiratory Innovative Drugs- Tianqing Suchang (Budesonide Suspension for Inhalation) is China’s first budesonide nebulized generic drug approved for marketing, breaking the long-term monopoly of branded drugs in the domestic market, and offering an effective, safe and economical high-end product for patients with chronic airway inflammation in China. The product has been included in the national Volume-based Procurement (“VBP”). The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the VBP, enabling its sales to achieve steady growth in 2024.- Tianyun (Colistimethate Sodium for Injection) is a first-to-market generic drug launched in 2021. It is China’s first colistimethate sodium for injection approved for marketing, and was successfully included in the NRDL in 2023. At present, only two products with the same generic name have been approved in China. The Group continued to expand its market coverage through active academic promotion, and Tianyun’s sales grew rapidly in 2024.Surgery/Analgesia Innovative Drugs- Zepolas (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. Sales of flurbiprofen cataplasms have maintained a growth trend in recent years and achieved breakthrough growth in 2024. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing in 2025.Others- In 2024, the tenth batch of VBP products accounted for only 1% of the Group’s total revenue, and the related risks have basically been removed. In addition, Anboni (Unecritinib Fumarate Capsules) and Anluoqing (Envonalkib Citrate Capsules), two category 1 innovative drugs independently developed by the Group, were newly included in the NRDL and are expected to benefit more patients.HONG KONG, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharm” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2024.During the year, the Group recorded revenue of approximately RMB28.87 billion, an increase of approximately 10.2% over last year. Profit attributable to the owners of the parent company was approximately RMB3.50 billion, a substantial increase of approximately 50.1% over last year. Earnings per share attributable to the owners of the parent company were approximately RMB19.13 cents, a significant increase of approximately 51.9% over last year, which was mainly driven by the notable growth in revenue and the gain on disposal of subsidiaries during the year. Excluding the profit attributable to the owners of the parent from the discontinued operations, the share of profits and losses of associates and joint ventures (net of related tax and non-controlling interests), one-off adjustments for the impairment and fair value changes of certain assets and liabilities (net of related tax and non-controlling interests), fair value losses/(gains) of current equity investments (net of related tax and non-controlling interests), share-based payments (net of related tax and non-controlling interests), effective interest expenses and exchange (gain)/loss of the convertible bond debt component, adjusted non-HKFRS profit attributable to the owners of the parent was approximately RMB3.46 billion, an increase of approximately 33.5% over last year. The Group's liquidity remains strong, with total fund reserve at approximately RMB24.11 billion, including cash and bank balances classified under current assets of approximately RMB9.57 billion, bank deposit classified under non-current assets of approximately RMB9.37 billion, and the wealth management products of approximately RMB5.17 billion in aggregate.The Board of Directors has recommended a final dividend payment of HK4 cents per share (2023: HK3 cents). Together with the interim dividend of HK3 cents already paid, the total dividend for the year amounted to HK7 cents (2023: HK5 cents).Sales: Robust sales system continues to drive results  Achieves positive revenue growth for  generic drugsOn the strong foundation its generic drug business provides, the Group has comprehensively promoted innovation and transformation. The innovative products have kept boosting sales growth, with share of revenue climbing year after year. Revenue from innovative products amounted to RMB12.06 billion, up by 21.9% year-on-year, and accounted for 41.8% of the Group's total revenue.During the year, the sales of oncology medicines amounted to approximately RMB10.73 billion, representing approximately 37.2% of the Group’s revenue. The sales of surgery/analgesia and liver disease amounted to approximately RMB4.46 billion and RMB3.44 billion, respectively, representing approximately 15.4% and 11.9% of the Group's revenue, respectively. In addition, sales contributions from various areas such as respiratory, cardio-cerebral vascular medicines and others have continued to contribute to the Group's revenue. Among them, the sales of respiratory and cardio-cerebral vascular medicines accounted for approximately 10.9% and 7.5% of the Group's revenue, respectively.R&D: Pushes at full force innovative product development  Actively applies for various patentsThe Group has continued to focus its R&D efforts on new medicines in the four therapeutic areas of oncology, liver diseases, respiratory and surgery/analgesia. As at the end of the reporting period, the Group had 70 innovative products under development, including 39 oncology products, 7 liver disease products, 13 respiratory products, and 6 surgery/analgesia products, and 5 other products. In addition, the Group had 65 generic drug products in development.The Group also attaches tremendous importance to the protection of intellectual property rights and encourages its member enterprises to file patent applications in order to enhance the Group’s core competitiveness. During the reporting period, the Group filed 1,069 new patent applications and received 349 patent invention approvals. As at the end of the reporting period, the Group had accumulated 5,082 effective patents and patent applications and obtained 1,958 patent invention approvals.Prospects: Focuses on core business and innovation  Continues to promote dual-pronged approach in implementing globalization strategyThe Chinese pharmaceutical market has occupied a key position in the global pharmaceutical industry due to its huge volume and increasing market demand. In addition, as a strategic industry closely linked to the national economy and people’s livelihood, the pharmaceutical industry receives key support from national policies and incentives. Meanwhile, a series of policies is expected to broaden the pricing flexibility of innovative drugs, improve their accessibility, and create a wider market prospect for such drugs.Committed to its vision “to be a leading global pharmaceutical company through delivering innovative therapies for patients”, the Group has adhered to comprehensive innovation, stepped up its R&D investment, and continued to strengthen its internal R&D capabilities. It has now built a comprehensive pipeline and product portfolio. At the same time, the Group has vigorously promoted business development and strategic cooperation, striving to become the best partner for global pharmaceutical and biotechnology enterprises.At present, the Group has entered the harvest period of its innovative development. It is expected that by 2027, the number of innovative products launched to the market will exceed 30, with revenue from innovative products accounting for over 55% of total revenue. This will further strengthen the Group’s dominant position in the four main therapeutic areas and provide strong impetus for the future sustainable growth. In addition, the Group has advanced its digitalization strategy with artificial intelligence (AI) as the core driving force. It has finished locally deploying cutting-edge AI models including DeepSeek and ChatGPT, and optimized key business such as cross-departmental collaboration, thereby significantly improving operational efficiency.Meanwhile, the Group adopts its dual-pronged globalization strategy to accelerate innovation and development. The Group will bring global pharmaceutical innovations to China to benefit Chinese patients, while also expanding its presence in international markets to target unmet clinical needs worldwide.Looking ahead, the Group will further focus on its core business and innovation, and continue to improve R&D efficiency and quality in the four major therapeutic areas. It will also actively accelerate the deployment for globalization of its business to drive rapid business growth and steady performance improvement, and contribute to the development of the global pharmaceutical industry.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading Chinese pharmaceutical company continuing to invest in Oncology, Liver Diseases, Respiratory and Surgery/Analgesia, exploring innovative therapies to improve the lives of patients. The company has strong manufacturing capabilities and broad patient access across China. Sino Biopharmaceutical Limited is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index; In 2020, it was selected as a constituent stock of Hang Seng Connect Biotech 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index. The company has been listed in the “Top 50 Global Pharmaceutical Enterprises” published by the authoritative American magazine Pharmaceutical Manager for six consecutive years, and has been rated as the “Top 50 Best Companies in Asia Pacific” by Forbes (Asia) for three consecutive years.For more information, please visit: www.sinobiopharm.com Copyright 2025 ACN Newswire via SeaPRwire.com.

SAN DIEGO, CA, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI), a world leader in unmanned aircraft systems (UAS), has received the prestigious EMAR/FR 145 Maintenance Organization Approval for component maintenance from the French Military Continuing Airworthiness Authority, DSAE. This approval underscores GA-ASI's commitment to the highest standards of safety, compliance, and operational excellence in military aviation.The EMAR framework is a set of regulations developed from commercial aerospace standards (FAA/EASA) that are designed to ensure airworthiness for European military aircraft. It establishes a common airworthiness framework recognized by military airworthiness authorities worldwide. EMAR/FR 145 certification authorizes maintenance organizations to perform critical maintenance tasks while ensuring strict adherence to safety, reliability, and documentation requirements.GA-ASI's EMAR/FR 145 approval allows the company to issue EMAR Form 1s (Return to Service forms) for components serviced by the approved maintenance organization, confirming the safety and airworthiness of the equipment. This recognition applies to GA-ASI's maintenance activities at its Poway and Adelanto, California, facilities and covers CAT C (component maintenance) services."This approval is a significant achievement for GA-ASI, positioning the company to better serve international customers, especially military users of our MQ-9A and MQ-9B UAS platforms," said Sam Richardson, GA-ASI vice president of Sustainment. "The ability to leverage the EMAR/FR 145 certification streamlines the company's processes, reduces costs, and accelerates future airworthiness pursuits, as many future customers will recognize this certification rather than requiring a full, independent certification process."By obtaining EMAR/FR 145 approval, GA-ASI further demonstrates its ability to meet the stringent demands of the global defense market. The framework's widespread recognition ensures that GA-ASI can expand operations and offer high-quality, compliant maintenance services to international customers, ultimately driving company growth in global markets.This certification offers significant operational and financial benefits for both GA-ASI and its customers. For GA-ASI, the approval reduces future oversight costs by leveraging the DSAE Audit Team's oversight activities, ensuring a more efficient and cost-effective certification process for future non-French EMAR customers. For customers, the EMAR/FR 145 approval provides a framework recognized internationally, offering a streamlined maintenance certification process. The recognition agreements between EMAR and non-EMAR countries allow future customers to leverage GA-ASI's French approval, saving time and resources compared to a full certification effort.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle® 25M, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.

Highlights of the Global Offering:- The Hong Kong Public Offering is expected to close at 12:00 noon (at 11:30 a.m. for completing electronic applications under the White Form eIPO service) on Wednesday, 26 March 2025;- Offer Price Range: HK$2.50 to HK$3.00 per Share;- The Shares will be traded in board lots of 1,000 Shares each;- Maximum net proceeds will be approximately HK$117.7 million (before any exercise of the Over-allotment Option);- Dealings in the Shares on the Main Board of the Hong Kong Stock Exchange are expected to commence on Monday, 31 March 2025;- Red Solar Capital Limited is the Sole Sponsor.HONG KONG, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - Jiangsu Horizon Chain Supermarket Company Limited (the “Company”, stock code: 2625) today announces its Global Offering and the listing of Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).Jiangsu Horizon Chain Supermarket Company Limited is a wholesaler of grains and oil headquartered in Yangzhou, with retail operations of supermarket and convenience stores focusing on the central region of Jiangsu Province under the brand 'Hongxinlong'. According to the Industry Report, the Company ranked second among supermarket operators in Yangzhou in terms of sales in 2023 with a market share of approximately 9.1%, the fifth among supermarket operators in the central region of Jiangsu Province in terms of sales in 2023 with a market share of approximately 2.3%, and around the twentieth among supermarket operators in Jiangsu province in terms of sales in 2023 with a market share of approximately 0.4%.Jiangsu Horizon Chain Supermarket Company Limited plans to offer an aggregate of 53,562,000 Shares (subject to Over-allotment Option) under the Global Offering, of which 48,205,000 Shares (subject to reallocation and the Over-allotment Option) will be offered by way of International Placing, and 5,357,000 Shares (subject to reallocation) will be offered in the Hong Kong Public Offering. The Offer Price will not be more than HK$3.00 per Share and is currently expected to be not less than HK$2.50 per Share, with the board lot size of 1,000 sharesThe Hong Kong Public Offering commenced on Friday, 21 March 2025 and is expected to close at 12:00 noon (at 11:30 a.m. for completing electronic applications under the White Form eIPO service) on Wednesday, 26 March 2025. Dealings in H Shares on the Stock Exchange are expected to commence on Monday, 31 March 2025.Assuming the Over-allotment Option is not exercised at all, if the Offer Price is set at HK$3.00 per Share (being the high end of the Offer Price range), the net proceeds from theGlobal Offering will increase to approximately HK$117.7 million. The Company intends to apply the net proceeds for the following purposes:- Approximately 30.9% will be used for the opening of new Retail Stores, including store renovation, purchase of shelves, purchase of cold storage facilities, lightings, air-conditioning, CCTV surveillance system and POS system and installation of fire safety system.- Approximately 41.2% will be used for establishing a new distribution centre including acquiring a parcel of land for the construction of the New Distribution Centre, acquiring shelves, lightings and ancillary facilities and installing fire safety system.- Approximately 26.8% will be used for establishing a new central kitchen, including the construction of the New Central Kitchen, acquiring machines and equipment, acquiring and installing fire safety system, ventilation system, cold storage facilities, utilities, air-conditioning, CCTV surveillance system and ancillary facilities, and acquiring additional vehicles for the delivery of meals to the customers.- Approximately 1.1% will be used for enhancing the ERP system and infrastructure systems to improve operational efficiency.The Company has successfully procured cornerstone investor Top Legend SPC, Top Legend has agreed to subscribe for such number of H Shares which may be subscribed with an aggregate amount of US$5.0 million at the Offer Price (including brokerage, SFC transaction levy and Stock Exchange trading fee). The lock-up period shall last for a duration of six months.Red Solar Capital Limited is the Sole Sponsor. Red Solar Capital Limited and CMBC Securities Company Limited are the Joint Overall Coordinators, Joint Global Coordinators, Joint Bookrunners, and Joint Lead Managers. CCB International Capital Limited is the Joint Global Coordinators, Joint Bookrunners, and Joint Lead Managers. CMB International Capital Limited, uSMART Securities Limited, Star River Securities Limited, Eddid Securities and Futures Limited, Innovax Securities Limited, and Long Bridge HK Limited are the other Joint Bookrunners and Joint Lead Managers. Copyright 2025 ACN Newswire via SeaPRwire.com.

Highlights:Drill hole CS25-027 encountered seven (7) spodumene pegmatite intervals, with the widest continuous interval of 179.6 metres (m), followed by two additional intervals of 58 m and 91.8 m of continuous spodumene pegmatite.Drill hole CS25-024/24A intersected a total of six (6) individual spodumene pegmatite intervals, with the widest continuous interval of 39.5 m.Drill hole CS25-025 encountered nine (9) spodumene pegmatite intervals, with the widest continuous interval of 20.4 m.Drill hole CS25-026 encountered 10 spodumene pegmatite intervals, with the widest continuous interval of 21.2 m.Assays are pending on the approximately 2,570 m of core drilled in the first four (4) holes completed to date in the winter drill campaign at the Cisco Project.Drilling continues with step outs to both the east and south.Vancouver, BC, Mar 19, 2025 - (ACN Newswire via SeaPRwire.com) - Q2 Metals Corp. (TSXV:QTWO)(OTCQB:QUEXF)(FSE:458) ("Q2" or the "Company") is pleased to announce the completion of the first four holes of the winter 2025 expansion drilling campaign at the Company's Cisco Lithium Project (the "Project" or the "Cisco Project"), located within the greater Nemaska traditional territory of the Eeyou Istchee James Bay, Quebec, Canada.Multiple wide intercepts of continuous spodumene pegmatite were encountered within a total of 2,570 metres of drilling completed to date, significantly increasing the extent of previously encountered mineralization (see Figure 1). All holes intercepted pegmatites with visual indications of spodumene mineralization identified."We are extraordinarily pleased with these initial findings from our winter campaign which has not only produced one of our top holes in terms of the total amount of spodumene pegmatite per hole, but continues to provide important information about the mineralization at Cisco," said Q2 Metals President and CEO Alicia Milne. "We are continuing to explore the robust and continuous nature of Cisco's mineralization with additional step outs to both the south and east.""The first four holes of the winter drill program have expanded the strike length of the mineralized system and has confirmed that it continues to extend to the south, further increasing Cisco's potential scale," said Q2 VP Exploration Neil McCallum. "Hole-27, with 179.6 metres of continuous spodumene pegmatite, plus an additional 58 and 91.8 metres of continuous spodumene pegmatite, lends further support to our theory of a south-trending mineralized system, which now extends over a kilometre."Figure 1. Map of Drilling area, Cisco ProjectWinter 2025 Exploration Program OverviewThe current 2025 Winter Program is targeting 6,000 - 8,000 m of drilling with 200 - 400 m step outs with the primary objective of expanding upon the exceptionally promising drill results from the inaugural 2024 campaign, which included:Drill hole CS-24-018 - 215.6 m at 1.69% Li 2 O;Drill hole CS-24-021 - 347.1 m at 1.35% Li 2 O; andDrill hole CS-24-023 - 188.6 m at 1.56% Li 2 O.One diamond drill rig tested to the southwest of drill hole CS-24-023 to define the strike length:Drill hole CS25-025 was collared approximately 275 m south of hole CS24-023; andDrill hole CS25-027 is located 200 m southeast of hole CS25-025.This fence of holes was designed to test the southward extension of the large and wide mineralized system and did so successfully with hole CS25-027's widest continuous interval of 179.6 m of spodumene-bearing pegmatite.One diamond drill rig tested to the east of drill holes CS-24-018 and CS-24-021 to define potential additional parallel pegmatite zones:Drill hole CS25-024A was drilled as a follow-up to hole CS25-024 which was lost due to difficult drilling conditions. It was collared approximately 400 m southeast of hole CS24-022; andDrill hole CS25-026 was collared approximately 400 m from CS24-021 and 285 m north of hole CS25-024A.Drilling remains ongoing, with step outs continuing both east and south.Figure 2. Drill Rig Locations at the Cisco Lithium ProjectSummary of Spodumene-Bearing Pegmatite IntervalsThe pegmatite intervals (greater than 2 m) of drill holes CS-25-024A to 027 are reported below in detail (Table 1).Table 1. Summary of Spodumene-Pegmatite Intervals, Cisco ProjectThe mineralized intervals in all the holes are not necessarily representative of the true width and the modelled pegmatite zones are being refined with every additional hole.Cautionary Statement: The presence of pegmatites does not confirm the presence of lithium (spodumene or other lithium minerals). Pegmatites are fractionated coarse grained igneous rocks commonly associated with lithium mineralization; however, many pegmatites do not contain mineralization. The presence of any mineralization can only be confirmed with assaying.The geological team has completed the core cutting and logging of holes CS25-024/24A to CS25-027 and the samples have been dispatched to the SGS Canada preparation laboratory located in Val-d'Or, QC for mineral analysis to confirm the presence of lithium.Figure 3. Core from the Current Drill Program at Cisco Lithium ProjectSampling, Analytical Methods and QA/QC ProtocolsAll drilling was conducted using diamond drill rig with NQ sized core and all drill core samples are shipped to SGS Canada's preparation facility in Val D'Or, Quebec, for standard sample preparation (code PRP92) which includes drying at 105°C, crushing to 90% passing 2 mm, riffle split 500 g, and pulverize 85% passing 75 microns. The pulps are then shipped by air to SGS Canada's laboratory in Burnaby, BC, where the samples are homogenized and subsequently analyzed for multi-element (including Li and Ta) using sodium peroxide fusion with ICP-AES/MS finish (code GE_ICM91A50). The reported Li grade will be multiplied by the standard conversion factor of 2.153 which results in an equivalent Li 2 O grade. Drill core was saw-cut with half-core sent for geochemical analysis and half-core remaining in the box for reference. The same side of the core was sampled to maintain representativeness.A Quality Assurance / Quality Control (QA/QC) protocol following industry best practices was incorporated into the sampling program. Measures include the systematic insertion of quartz blanks and certified reference materials (CRMs) into sample batches at a rate of approximately 5% each. Additionally, analysis of pulp-split and reject-split duplicates was completed to assess analytical precision. The QP has verified the QA/QC results of the analytical work.Drill Hole Collar InformationThe summary of drill holes completed to date, including basic location and dip/azimuth is detailed below (Table 2).Coordinates are in UTM NAD83, zone 18All holes are NQ-Size diamond drill coreAzimuth and dip are reported as planned, and will deviate down-holeReported hole depths are subject to minor changes based on final core observationsTable 2. Summary of Drill Hole Collar Information, Cisco Project (CS25-024-027)Upcoming EventsIgnite Investment SumitThe Company will be attending the Ignite Investment Summit in Hong Kong March 26-27, 2025.For more information, click here.Future Facing Commodities ConferenceThe Company will be attending and exhibiting at the Tribeca Future Facing Commodities 2025 Conference in Singapore on April 1-3, 2025.For more information, click here.About Q2 Metals CorpQ2 Metals is a Canadian mineral exploration company focused on the Cisco Lithium Project located within the greater Nemaska traditional territory of the Eeyou Istchee, James Bay, Quebec, Canada where drilling is currently underway.The Cisco Project is comprised of 767 claims, totaling 39,389 hectares. The main mineralized zone is just 6.5 kilometres ("km") away from the Billy Diamond Highway and transects the Project. The town of Matagami, which features direct rail link to much of James Bay, is approximately 150 km to the south.Cisco has district-scale potential with an already identified mineralized zone and 2024 discovery drill results that include:120.3 metres at 1.72% Li 2 O (hole CS-24-010);215.6 metres at 1.69% Li 2 O (hole CS-24-018);347.1 metres at 1.35% Li 2 O (hole CS-24-021); and188.6 metres at 1.56% Li 2 O (hole CS-24-023)The Cisco Project is situated along the Frotet Evans Greenstone Belt, comprised of a volcanic package dominated by mafic to felsic metavolcanic rocks, of the southern James Bay Lithium District, the same belt that hosts the Sirmac and Moblan lithium deposits, located 130 km and 180 km away, respectively.FOR FURTHER INFORMATION, PLEASE CONTACT:Alicia Milne, President & CEO, Alicia@Q2metals.comJason McBride, Corporate Communications, Jason@Q2metals.comChris Ackerman, Corporate Communications, Chris@Q2metals.comTelephone: 1 (800) 482-7560, E-mail: info@Q2metals.com www.Q2Metals.comClick to follow us online:X, LinkedIn, Facebook, and InstagramQualified PersonNeil McCallum, B.Sc., P.Geol, a registered permit holder with the Ordre des Géologues du Québec and Qualified Person as defined by NI 43-101 ("QP"), has reviewed and approved the technical information in this news release. Mr. McCallum is a director and VP Exploration for Q2.Forward-Looking StatementsThis news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian legislation. Forward-looking statements are typically identified by words such as: "believes", "expects", "anticipates", "intends", "estimates", "plans", "may", "should", "would", "will", "potential", "scheduled" or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. Accordingly, all statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, any statements or plans regard the geological prospects of the Company's properties and the future exploration endeavors of the Company. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions.Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in such forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date specified in such statement. Forward-looking statements in this news release include, but are not limited to, drilling results on the Cisco Project and inferences made therefrom, the potential scale of the Cisco Project, the focus of the Company's current and future exploration and drill programs, the scale, scope and location of future exploration and drilling activities, the Company's expectations in connection with the projects and exploration programs being met, the Company's objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, variations in ore grade or recovery rates, changes in project parameters as plans continue to be refined, unsuccessful exploration results, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, delays in receiving government approvals, unanticipated environmental impacts on operations and costs to remedy same. Readers are cautioned that mineral exploration and development of mines is an inherently risky business and accordingly, the actual events may differ materially from those projected in the forward-looking statements. Additional risk factors are discussed in the section entitled "Risk Factors" in the Company's Management Discussion and Analysis for its recently completed fiscal period, which is available under Company's SEDAR profile at www.sedarplus.ca.Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.SOURCE: Q2 Metals Corp. Copyright 2025 ACN Newswire via SeaPRwire.com.

PUTRAJAYA, Malaysia, Mar 19, 2025 - (ACN Newswire via SeaPRwire.com) - This festive season, Spritzer Sparkling is set to make Hari Raya celebrations more meaningful with its latest campaign "Raya Lebih Bermakna Bersama Spritzer Sparkling". The campaign which encourages Malaysians to think about how they express love to their family and friends focuses on how simple thoughtful things and moments in our busy lives can add more joy and meaning amongst families and friends.Spritzer Sparkling ambassadors, Naim Daniel, Dato' Jalaluddin Hassan, and Zara ZyaSpritzer Sparkling is also adding to the Raya cheer through Malaysian film and television fans by hosting a special Meet & Greet with renowned actors, Dato’ Jalaluddin Hassan, Naim Daniel and Zara Zya, who are also its brand ambassadors starring in its latest short film. A Heartfelt Film About Family & FestivitiesWith Hari Raya around the corner, Spritzer Sparkling reminds us to take a moment to reflect on how our words and actions affect our loved ones, while we focus on traditions like preparing feasts and visiting loved ones. Spritzer Sparkling presents "Raya Lebih Bermakna – Mana Adam", a touching short film about family and festivities starring its three brand ambassadors. The story follows a mother’s frantic search for her missing teenage son, Adam, on the morning of Hari Raya. As she expresses her frustration in front of the family, the truth unfolds in an unexpected yet emotional revelation. The Spritzer short film is now available on the Spritzer Group’s YouTube channel now!Celebrate Raya with Spritzer SparklingAs part of the heartwarming campaign, Spritzer Sparkling welcomes Malaysian fans to celebrate Raya and embrace the meaningfulness of the season with the stars of the moving short film. Fans are invited to an exciting Meet & Greet with Dato’ Jalaluddin Hassan, Naim Daniel and Zara Zya, where they will have the chance to capture memorable moments, celebrate the festive joy together and enjoy exclusive rewards. The Meet & Greet will take place in IOI City Mall, Putrajaya on 22nd March 2025 from 2.00pm to 4.00pm.Exclusive Raya Perks for EveryoneTo make the season even more special, Spritzer Sparkling is offering customers a free Golden Bowl for every purchase of Spritzer Sparkling products worth RM12 throughout the campaign from 1st March to 30th April 2025. Available in Original and Lemon flavours, Spritzer Sparkling is not just a guilt-free refreshment—free from sweeteners and calories—but also a versatile ingredient for your Raya celebrations. Discover three refreshing and delicious Raya recipes—Sparkling ABC Ros, Sparkling Teh Halia, and Sparkling Selasih Biru—featuring Spritzer Sparkling here, perfect for adding a creative twist to your festive spread!Spritzer Sparkling Raya GiveawayJoin us in making this Raya more meaningful – meet your favourite stars, enjoy an inspiring short film, and take part in Spritzer Sparkling’s exclusive campaign. Don’t forget to mark your calendars and be at IOI City Mall, Putrajaya, on 22nd March 2025, from 2.00pm to 4.00pm for an unforgettable experience!For more information, please visit the microsite here.– End –About SpritzerSpritzer, Malaysia’s No.1 bottled water brand since 1989, sources its water from a 430-acre tropical rainforest in Taiping. The water undergoes a natural filtration process through underground rocks for over 15 years, enriching it with essential minerals like Silica, which benefits skin, bones, hair, and nails.As a leader in smart manufacturing, we use advanced technology to ensure quality and safety. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to sustainability. Tested annually by SIRIM, our products are free from microplastics.Spritzer offers a full range of products, from Natural Mineral Water and Sparkling Water to Distilled Water and Fruit-flavoured Beverages, catering to every lifestyle and occasion. With a vision to become a circular brand by 2030, we are committed to sustainability and delivering quality you can trust.Spritzer—nature, innovation, and sustainability in every bottle. For more information, please visit www.spritzer.com.my. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - “Fencing Plus” Training Programme, title-sponsored by CTF Life and organised by Kai Tak Sports Initiative, aims to identify children aged 6 to 10 with potential in fencing through structured selection and training process. The programme seeks to nurture the next generation of elite fencing athletes, who will represent Team Hong Kong, China, to become future world champions while promoting the culture of “Sports for All” and enhancing professionalism. Applications are now open (starting 18 Mar), with the goal of recruiting 600 promising fencing students.Two-Year Structured Training Led by Hong Kong Fencing Team Team ManagerThe "Fencing Plus" Training Programme (the Programme), organised by Kai Tai Sports Initiative—the community project of Kai Tak Sports Park—and title-sponsored by CTF Life for the first time this year, aims to select students with fencing potential through a scientific approach and provide them with nearly two years of structured training. In the later stages of the Programme, students will have the opportunity to compete against fencers from different countries and regions, honing their skills while embracing the spirit of true sportsmanship and overcoming challenges. Additionally, CTF Life will support selected children from underprivileged families from Kowloon East to participate in the programme.The Programme will be led by Antonio Lam, Team Manager of Hong Kong Fencing Team, Asian Games Double Bronze Medalist and Olympic Games representative for the Hong Kong Fencing Team, will serve as the Head Coach of the Programme. He will guide a team of professional coaches to provide tailored instructions, analyse the potential of students, and deliver an extensive training framework, inspiring a spirit of sportsmanship in every participant.First Stage Selection Begins in May: No Fencing Experience RequiredThe first stage of the Programme, the "Fencing Plus" Training Programme Selection Day, will be held on 4 May, 2025 (Sunday) from 10:00 a.m. to 5:00 p.m. at the Kai Tak Arena. On that day, children will participate in a full-day interactive test assessing their physical fitness ability, coordination, and reaction assessments. No prior fencing experience is required to participate.From now until 31 March, 2025, guardians can submit application for their children by registering to become members of CTF Life‧CIRCLE and donating HK$100 to the "Kai Tai Sports Initiative Foundation", which will be used to support on community activities. Qualified students will undergo structured training in basic and advanced stages. The programme features exclusive quotas for CTF Life‧CIRCLE members, while Diamond and Gold members can enjoy priority enrolment and participation, accessing to premium experiences.Progressive Training to Unlock Potential: Leading "MyFuture Fencers" to Compete InternationallySelected students will undergo basic and advanced training stages, after which they will have the opportunity to participate in the CTF Life “Fencing Plus” Cup. Outstanding performers will be selected for an 18-month elite training and the chance to get into Hong Kong Under-14 professional fencing training scheme.  - Stage Two: Basic Training, with a commemorative certificate upon meeting the required standard- Stage Three: Advanced Training, with a commemorative certificate upon meeting the required standard- Stage Four: CTF Life “Fencing Plus” Cup, with registration fee for selected participants from the programme will be fully sponsored by CTF Life- Stage Five: Elite Training Programme to nurture future sports starsRegistration Link:https://lifepillars.ctflife.com.hk/pillars/edutainmentThe content and schedule of the above programme are subject to change without prior notice.About CTF LifeChow Tai Fook Life Insurance Company Limited (“CTF Life”) is proud of its rich, 40-year legacy in Hong Kong. CTF Life is a wholly-owned subsidiary of CTF Services Limited and one of the most well-established life insurance companies in Hong Kong. As a member of Chow Tai Fook Enterprises Limited, CTF Life consistently strengthens its collaboration with the diverse conglomerate of the Cheng family (“Chow Tai Fook Group” or “the Group”) to support customers and their loved ones in navigating life’s journey with personalised planning solutions, lifelong protection and diverse lifestyle experiences. By leveraging the Group’s robust financial strength and strategic investments across the globe, CTF Life aspires to become a leading insurance company in Asia while continuously creating value beyond insurance. Copyright 2025 ACN Newswire via SeaPRwire.com.

- Launch of TEC’s 11th centre in Singapore, enhancing its footprint in the region.- Contemporary design featuring high-end amenities, including ergonomic furnishings and innovative workspaces.- Debut of Origo Café and Bar, showcasing an innovative array of refreshments to enhance the member experience.Singapore, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - The Executive Centre (TEC), Asia’s leading premium flexible workspace provider, is delighted to announce the opening of its 11th centre in Singapore, located on level 22 of the prestigious Ocean Financial Centre. This expansive new centre encompasses over 21,000 square feet, and accommodates more than 300 workstations, further solidifying TEC’s presence within one of the Southeast Asia’s most sought-after business districts.Ocean Financial Centre is already home to three TEC centres, with occupancy levels close to 95%. This underscores the company’s unwavering commitment to delivering exceptional workspace solutions in this iconic building and to provide additional spaces to meet the growing demand. This latest centre opening is part of TEC's strategic expansion initiative, with more centres slated to open later this year in Singapore.The design of the new centre evokes contemporary elegance, featuring organic curves and warm wood elements in the main lounge area, creating an inviting ambiance for its members. In alignment with TEC's premium positioning, the centre is adorned with high-end finishes, height-adjustable standing desks, and ergonomic Herman Miller chairs, ensuring an unparalleled working environment.A notable highlight of the new centre is the debut of Origo Café and Bar, which presents an innovative array of refreshments, including a dedicated ice cream bar and craft beers on tap. This centre is The Executive Centre’s first in Singapore to hold a liquor license, enabling distinctive food and beverage pairings that transcend the traditional TEC Barista Bar experience. Additionally, Origo-branded coffee beans and merchandise will also be available for sale.In line with TEC's commitment to sustainability, the new centre incorporates Framery phone booth pods which provide exceptional soundproofing and optimal ventilation while minimising energy consumption. These environmentally conscious booths are fully recyclable at the end of their lifecycle, reflecting TEC’s dedication to sustainable innovation.Yvonne Lim, Managing Director of Southeast Asia at The Executive Centre, remarked, "We are profoundly excited to unveil our new centre at Ocean Financial Centre. This expansion not only epitomizes our commitment to providing exceptional workspace solutions but also enriches our community with innovative offerings such as Origo Café and Bar. We envision this centre as a vibrant nexus for professionals seeking a flexible and inspiring work environment."The Executive Centre’s new location at Ocean Financial Centre is poised to redefine the flexible workspace experience in Singapore, fostering collaboration and innovation among its esteemed members.About The Executive CentreThe Executive Centre (TEC) is Asia’s premium flexible workspace provider, opened its doors in Hong Kong in 1994 and today boasts over 220+ Centres in 36 cities and 16 markets. It is the third largest serviced office business in Asia.The Executive Centre caters to ambitious professionals and industry leaders looking for more than just an office space - they are looking for a place for their organisation to thrive. TEC has cultivated an environment designed for success with a global network spanning Greater China, Southeast Asia, North Asia, South Asia, the Middle East, and Australia, with sights to go further and grow faster. Each Executive Centre offers a prestigious address with the advanced infrastructure to pre-empt, meet, and exceed the needs of its Members. Walking with Members through every milestone and achievement, The Executive Centre empowers ambitious professionals and organisations to succeed.Privately owned and headquartered in Hong Kong, TEC provides first class Private and Shared Workspaces, Business Concierge Services, and Meeting & Events facilities to suit any business' needs.www.executivecentre.comPress EnquiriesThe Executive CentrePebble LeePebble_lee@executivecentre.com / +852 3951 9888 Copyright 2025 ACN Newswire via SeaPRwire.com.